Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quelle place pour l’automatisation intelligente et l’intelligence artificielle pour préserver et renforcer l’expertise en vigilance devant l’augmentation des déclarations ?
Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F. Pariente A, et al. Among authors: molimard m. Therapie. 2023 Jan-Feb;78(1):115-129. doi: 10.1016/j.therap.2022.11.003. Epub 2022 Nov 25. Therapie. 2023. PMID: 36577617 French. No abstract available.
What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F. Pariente A, et al. Among authors: molimard m. Therapie. 2023 Jan-Feb;78(1):131-143. doi: 10.1016/j.therap.2022.11.004. Epub 2022 Nov 25. Therapie. 2023. PMID: 36572627
Quelles actions pour lutter contre la désinformation sur les produits de santé ?
Micallef J, Maisonneuve H, Muller S, Molimard M, Bégaud B, Cabut S, Daban M, Drici MD, Gatignol C, Grumblat A, Guaspare-Cartron C, Lasserre B, Mebarki A, Pons C, Prabonnaud F, Raynaud C, Saint-Lary O. Micallef J, et al. Among authors: molimard m. Therapie. 2024 Jan-Feb;79(1):75-86. doi: 10.1016/j.therap.2023.10.004. Epub 2023 Oct 29. Therapie. 2024. PMID: 37985308 French. No abstract available.
Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study).
Demoly P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Devillier P. Demoly P, et al. Among authors: molimard m. Lancet Reg Health Eur. 2024 Apr 26;41:100915. doi: 10.1016/j.lanepe.2024.100915. eCollection 2024 Jun. Lancet Reg Health Eur. 2024. PMID: 38707866 Free PMC article.
What should be done to combat misinformation about health products?
Micallef J, Maisonneuve H, Muller S, Molimard M, Bégaud B, Cabut S, Daban M, Drici MD, Gatignol C, Grumblat A, Guaspare-Cartron C, Lasserre B, Mebarki A, Pons C, Prabonnaud F, Raynaud C, Saint-Lary O. Micallef J, et al. Among authors: molimard m. Therapie. 2024 Jan-Feb;79(1):87-98. doi: 10.1016/j.therap.2023.11.001. Epub 2023 Nov 10. Therapie. 2024. PMID: 38114387
A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort.
Devillier P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Demoly P. Devillier P, et al. Among authors: molimard m. Expert Rev Clin Immunol. 2024 Apr;20(4):405-412. doi: 10.1080/1744666X.2023.2294040. Epub 2023 Dec 19. Expert Rev Clin Immunol. 2024. PMID: 38112340
267 results